IRIS
CASCINU, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.021
AS - Asia 7.819
NA - Nord America 6.670
SA - Sud America 2.293
Continente sconosciuto - Info sul continente non disponibili 528
AF - Africa 182
OC - Oceania 12
AN - Antartide 1
Totale 25.526
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.321
RU - Federazione Russa 4.472
SG - Singapore 2.664
CN - Cina 2.324
BR - Brasile 1.883
HK - Hong Kong 1.053
IT - Italia 895
VN - Vietnam 847
SE - Svezia 782
RO - Romania 550
FR - Francia 383
BD - Bangladesh 322
DE - Germania 271
AR - Argentina 167
GB - Regno Unito 165
CA - Canada 143
IN - India 143
FI - Finlandia 118
MX - Messico 101
ID - Indonesia 85
ZA - Sudafrica 70
EC - Ecuador 68
AT - Austria 64
NL - Olanda 63
PL - Polonia 56
ES - Italia 53
CO - Colombia 51
JP - Giappone 50
TR - Turchia 47
IQ - Iraq 46
VE - Venezuela 33
IE - Irlanda 31
UA - Ucraina 30
CL - Cile 27
PK - Pakistan 27
MA - Marocco 26
PY - Paraguay 26
UZ - Uzbekistan 25
EG - Egitto 22
IR - Iran 19
MY - Malesia 19
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 17
JM - Giamaica 17
KE - Kenya 17
LT - Lituania 17
UY - Uruguay 17
NP - Nepal 15
PE - Perù 15
CR - Costa Rica 14
TN - Tunisia 14
AL - Albania 13
AU - Australia 12
DZ - Algeria 11
JO - Giordania 11
NI - Nicaragua 11
PH - Filippine 11
AZ - Azerbaigian 10
HN - Honduras 10
IL - Israele 10
MD - Moldavia 10
EU - Europa 9
BY - Bielorussia 8
OM - Oman 8
PR - Porto Rico 8
TT - Trinidad e Tobago 8
AO - Angola 7
BB - Barbados 7
BE - Belgio 7
SV - El Salvador 7
TH - Thailandia 7
KZ - Kazakistan 6
LB - Libano 6
PT - Portogallo 6
BO - Bolivia 5
PA - Panama 5
CH - Svizzera 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
PS - Palestinian Territory 4
TW - Taiwan 4
XK - ???statistics.table.value.countryCode.XK??? 4
BM - Bermuda 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
GA - Gabon 3
HR - Croazia 3
KG - Kirghizistan 3
KR - Corea 3
KW - Kuwait 3
SN - Senegal 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BS - Bahamas 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GR - Grecia 2
Totale 24.985
Salva come PNG Salva come JPEG
Città #
Dallas 1.279
Singapore 1.230
Moscow 1.062
Hong Kong 1.044
Ashburn 675
San Jose 593
Council Bluffs 511
Shanghai 402
Hefei 368
Ho Chi Minh City 339
Beijing 329
Lauterbourg 321
Lawrence 314
Princeton 313
New York 291
Los Angeles 178
São Paulo 170
Hanoi 157
Santa Clara 147
Milan 144
Rome 106
Helsinki 95
Boardman 74
Chicago 70
Nuremberg 69
Munich 67
Orem 63
Rio de Janeiro 60
Warsaw 49
Guangzhou 46
Haiphong 44
Tokyo 42
Brooklyn 40
Omaha 39
Montreal 37
Belo Horizonte 36
Denver 36
Chennai 34
Houston 33
Stockholm 33
Brasília 32
Cesano Boscone 32
Da Nang 32
London 32
Mexico City 32
Naples 32
Phoenix 32
Poplar 32
Vienna 31
Dublin 30
Johannesburg 30
Toronto 30
Porto Alegre 28
Atlanta 27
The Dalles 26
Guayaquil 25
Buffalo 24
Curitiba 24
Frankfurt am Main 24
Tashkent 24
Campinas 23
Manchester 23
Amsterdam 22
Ankara 21
Boston 21
Dhaka 21
Guarulhos 21
Mumbai 21
Ribeirão Preto 21
Columbus 20
Tianjin 20
Biên Hòa 19
Quito 19
San Francisco 19
Thái Bình 19
Baghdad 17
Brescia 17
Buenos Aires 16
Cape Town 16
Montevideo 16
Salvador 16
Washington 16
Hortolândia 15
Shenzhen 15
Hải Dương 14
Nairobi 14
Palermo 14
Recife 14
Turku 14
Blumenau 13
Florence 13
Fortaleza 13
Genoa 13
Querétaro 13
Seattle 13
Turin 13
Xi'an 13
Contagem 12
Duque de Caxias 12
Hangzhou 12
Totale 12.183
Salva come PNG Salva come JPEG
Nome #
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 470
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 437
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 422
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 351
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 236
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 148
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 141
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 137
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 135
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 134
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 128
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 128
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 127
The evolving role of microsatellite instability in colorectal cancer: A review 125
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 123
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 123
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 123
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 123
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 122
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 121
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 117
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 116
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 116
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 115
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 115
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 114
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 114
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 114
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 113
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 111
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 111
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 111
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 111
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 111
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 110
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 110
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 109
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 108
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 107
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 106
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 105
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 105
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 104
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 104
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 103
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 103
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 102
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 101
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 101
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 100
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 98
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 98
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 97
Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma 97
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 97
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 96
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 95
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 95
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 94
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 94
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 94
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 93
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 93
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 93
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 92
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 91
5-Fluorouracil pharmacogenomics: still rocking after all these years? 91
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 90
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 90
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 89
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 89
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 89
Cholangiocarcinoma: new perspectives for new horizons 88
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 88
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 87
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 87
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 87
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 86
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 85
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 85
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 84
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity 84
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 83
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 81
BRAF-mutated colorectal cancer: Clinical and molecular insights 81
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 80
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 80
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 80
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 80
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 80
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 78
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 78
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi 77
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 77
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 77
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 76
Evaluation of prognostic factors for survival in transverse colon cancer 76
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi. 74
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 73
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 73
Totale 11.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.035
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022229 0 1 0 99 7 7 23 43 19 7 6 17
2022/20231.524 736 283 86 8 13 201 41 73 59 6 10 8
2023/2024684 23 38 88 84 43 148 11 61 9 28 46 105
2024/20255.209 624 116 62 58 94 428 1.068 459 831 774 304 391
2025/202616.121 1.098 1.505 1.452 2.200 1.126 540 1.179 1.079 4.012 675 570 685
2026/20271.488 722 766 0 0 0 0 0 0 0 0 0 0
Totale 25.526